Gynecologic and Obstetric Investigation
Original Article
Tubal Pathology: The Role of Hormonal Contraception, Intrauterine Device Use and Chlamydia trachomatis InfectionMerki-Feld G.S. · Gosewinkel A. · Imthurn B. · Leeners B.Department of Gynecology and Obstetrics, Endocrinology Clinic, University Hospital Zurich, Zurich, Switzerland
|
|
Gynecol Obstet Invest 2007;63:114–120
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: March 29, 2006
Accepted: August 08, 2006
Published online: November 08, 2006
Issue release date: February 2007
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Background: The aim of the present study was to identify a possible association between tubal pathology and the contraceptive methods previously used, especially third generation copper intrauterine devices (IUDs). Method: In this retrospective unmatched case-control study, use of contraceptive methods and Chlamydiatrachomatis antibody titres were compared in women with tubal occlusion (n = 84) and infertile women with tubal patency (n = 253) demonstrated by hysterosalpingography. Contraceptive methods were also compared to primiparous women with natural pregnancy. Results: A significantly higher percentage of women with tubal occlusion had previously used an IUD. Positive C. trachomatis antibody testing was found significantly more often in women with tubal occlusion. Neither hormonal contraceptives nor condoms were associated with an increased risk for uni- or bilateral tubal occlusion. Conclusion: In the present study, we observed an increased rate of tubal occlusions in previous IUD users. This should be considered in the contraceptive counseling of young and nulliparous women.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Vessey MP, Yeates D, Flavel R, et al: Pelvic inflammatory disease and the intrauterine device: findings in a large cohort study. Br Med J (Clin Res Ed) 1981;282:855–857.
- Lee NC, Rubin JL, Ory HW, et al: Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983;62:1–6.
- Kaufman DW, Watson J, Rosenberg L, et al: The effect of different types of intrauterine devices on the risk of pelvic inflammatory disease. JAMA 1983;250:759–762.
- Buchan H, Villard-Mackintosh L, Vessey M, et al: Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br J Obstet Gynecol 1990;97:780–788.
- Farley TMM, Rowe PJ, Rosenberg MJ, et al: Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet 1992;339:785–788.
- Hubacher D, Lara-Ricalde R, Taylor DJ, et al: Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561–567.
-
Doll H, Vessey M, Painter R: Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. Br J Obstet Gynecol 2001;108:304–314.
External Resources
- Burkman R: Intrauterine device use and the risk of pelvic inflammatory disease. Am J Obstet Gynecol 1980;138:861–863.
- Grimes DA: Intrauterine devices and upper-genital-tract infection. Lancet 2000;356:1013–1019.
- Sivin I, Stern J: Health during prolonged use of levonorgestrel 20 micrograms/d and the copper Tcu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70–77.
- Senanayake P, Kramer DG: Contraception and the etiology of pelvic inflammatory disease: new perspectives. Am J Obstet Gynecol 1980;138:852–860.
- Rubin GL, Ory HW, Layde PM: Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982;144:630–635.
- Kelaghan J, Rubin JL, Ory HW, et al: Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982;248:184–187.
- Henry-Suchet J: Hormonal contraception and pelvic inflammatory disease. Eur J Contracept Reprod Health Care 1997;2:263–267.
- Bahamondes L, Bueno JGR, Hardy E, et al: Identification of main risk factors for tubal infertility. Fertil Steril 1994;61:478–482.
- Baeten JM, Nyange PM, Richardson BA, et al: Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185:380–385.
- Cates W, Rolfs RT, Aral SO: Sexually transmitted disease, pelvic inflammatory disease and infertility: an epidemiologic update. Epidemiol Rev 1990;12:199–220.
- WHO Task Force on the Prevention and Management of Infertility: Tubal infertility: serologic relationship to post chlamydial and gonococcal infection. Sex Transm Dis 1995;22:71–77.
-
Bundesamt für Gesundheit. Bulletin 52/03. CH-3003 Bern.
- Pavletic AF, Wolner-Hanssen P, Paavonen J, Hawes SE, Eschenbach DA: Infertility following pelvic inflammatory disease. Infect Dis Obstet Gynecol 1999;7:145–152.
- Hubacher D, Grimes D, Lara-Ricalde R, et al: The limited clinical usefulness of taking a history in the evaluation of women with tubal factor infertility. Fertil Steril 2004;81:6–10.
- Mardh PA: Tubal factor infertility, with special regard to chlamydial salpingitis. Curr Opin Infect Dis 2004;17:49–52.
- Gijsen AP, Land JA, Goossens VJ, Leffers P, Bruggeman CA, Evers JL: Chlamydia pneumoniae and screening for tubal factor subfertility. Hum Reprod 2001;16:487–491.
- Thomas K, Coughlin L, Mannion PT, Haddad NG: The value of Chlamydia trachomatis antibody testing as part of routine infertility investigations. Hum Reprod 2000;15:1079–1082.
- Toye B, Laferriere C, Claman P, et al: Association between antibody to the chlamydial heat shock protein and tubal infertility. J Infect Dis 1993;168:1236–1240.
- Lichtenwalner AB, Patton DL, Cosgrove Sweeney YT, et al: Evidence of genetic susceptibility to Chlamydia trachomatis-induced pelvic inflammatory disease in pig-tailed macaque. Infect Immun 1997;65:2250–2253.
- Cohen CR, Sinei SS, Bukusi EA, et al: Human leukocyte antigen class II DQ alleles associated with Chlamydia trachomatis tubal infertility. Obstet Gynecol 2000;95:72–77.
- Faundes A, Telles E, Cristofoletti M, Faundes D, Castro S, Hardy E: The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998;58:105–109.
- Gump DW, Gibson M, Ashikaga T: Evidence of prior pelvic inflammatory disease and its relationship to Chlamydia trachomatis antibody and intrauterine contraceptive device use in infertile women. Am J Obstet Gynecol 1983;146:153–159.
- World Health Organization Task Force on the Prevention and Management of Infertility: Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. Sex Transm Dis 1995;22:71–77.
- Mol BW, Dijkman B, Wertheim P, Lijmer J, van der Veen F, Bossuyt PM: The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis. Fertil Steril 1997;67:1031–1037.
- Swart P, Mol BW, van der Veen F, et al: The accuracy of hysterosalpingography in the diagnosis of tubal pathology: a metaanalysis. Fertil Steril 1995;64:486–491.
- Lee NC, Rubin JL, Grimes DA: Measures of sexual behavior and the risk of pelvic inflammatory disease. Obstet Gynecol 1991;77:425–430.
- Shrikhande SN, Zodpey SP, Kulkarni HR: Risk factors and protective factors of pelvic inflammatory disease: a case-control study. Indian J Public Health 1998;42:42–47.
- Hubacher A, Grimes D, Roger L, et al: The limited clinical usefulness of taking a history in the evaluation of women with tubal factor infertility. Fertil Steril 2004;81:6–10.
- Westström L: Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975;121:707–713.
- Barlow REL, Cooke ID, Odukoya O: The prevalence of Chlamydia trachomatis in fresh tissue specimens from patients with ectopic pregnancy or tubal factor infertility as determined by PCR and in-situ hybridization. J Med Microbiol 2001;50:902–908.
Article / Publication Details
First-Page Preview
Received: March 29, 2006
Accepted: August 08, 2006
Published online: November 08, 2006
Issue release date: February 2007
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
